An open portfolio of interoperable, industry leading products

The Dotmatics digital science platform provides the first true end-to-end solution for scientific R&D, combining an enterprise data platform with the most widely used applications for data analysis, biologics, flow cytometry, chemicals innovation, and more.

Sample Size & Power Calculations

Calculate for a Variety of frequentist and Bayesian Design

Adaptive Design

Design and Analyze a Wide Range of Adaptive Designs

Milestone Prediction

Predict Interim Analysis Timing or Study Length

Randomization Lists

Generate and Save Lists for your Trial Design

Group Sequential and Promising Zone Designs

Calculate Boundaries & Find Sample Size. Evaluate Interim Data & Re-estimate Sample Size

Sample Size for Bayesian Statistics

Probability of Success (Assurance), Credible Intervals, Bayes Factors and more

Early Stage and Complex Designs

Sample size & operating characteristics for Phase I, II & Seamless Designs (MAMS)

Sample Size & Power Calculations

Calculate for a Variety of frequentist and Bayesian Design

Adaptive Design

Design and Analyze a Wide Range of Adaptive Designs

Milestone Prediction

Predict Interim Analysis Timing or Study Length

Randomization Lists

Generate and Save Lists for your Trial Design

Group Sequential and Promising Zone Designs

Calculate Boundaries & Find Sample Size. Evaluate Interim Data & Re-estimate Sample Size

Sample Size for Bayesian Statistics

Probability of Success (Assurance), Credible Intervals, Bayes Factors and more

Early Stage and Complex Designs

Sample size & operating characteristics for Phase I, II & Seamless Designs (MAMS)

antidepressant therapy

**Objective: **This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy.

**Year:** 2017

**Source:** Journal of Psychopharmacology

**Link:** https://journals.sagepub.com/doi/10.1177/0269881117722998**Protocol:** https://clinicaltrials.gov/ct2/show/NCT01435759

**Clinical Area:** Psychopharmacology

Sample Size Section in Paper/Protocol: |

““Participants meeting all of the randomization criteria were randomized 1:1:1:1:1 to |

Summary of Necessary Parameter Estimates for Sample Size Calculation:

Parameter |
Value |

Significance Level (2-Sided) | 0.1 |

Number of Doses | 5 (0mg, 10mg, 30mg, 50mg, 70mg) |

Number of Models | 4 (Emax, Linear, Logistic, Beta) |

Placebo Effect, δ 0 | 0.2 |

Max Treatment Effect, δ 1 | 3 |

Standard Deviation, σ | 8.1 |

Power | 80% |

**Step 1: **Select the MGT5 Multiple Comparisons Procedure - Modelling (MCP-Mod) table from the Select Test window.

This can be done

**Step 2:**Enter the parameter values in the main table for the sample size calculation taken from the study description.

First, complete the

An optional random seed is also specified here to allow replicable results.

Next, complete the Dose Levels and Candidate Models side table .

**Step 3:**Enter the

The analysis gives a sample size of 67 per dose group (335 in total). A mean power of 80.29% was achieved with this sample size. The per-model powers ranged from 75.258% (Linear Model) to 93.640% (Beta Model). The maximum effect dose was the 70mg final dose for Emax, Linear and Logistic while the Beta model achieved maximum effect at the 50mg dose. |

Note that in the original study, the required sample size per dose group was calculated as 68 (340 total). This slight difference is likely due to rounding.

**Step 4:**

Output Statement: |

"“ A total sample size of 335 is required to ensure a mean power of 80.29% for a MCP-Mod analysis rejecting the null hypothesis of no difference between doses using the multiple comparisons procedure (MCP) assuming a placebo dose-response effect of 0, a maximum dose-response effect (in the dose range) of 3 and a common (residual) standard deviation of 8.1 per dose and two-sided family-wise error rate of 0.1.” |

This analysis assumed 5 doses with the following sample sizes per dose:

**Doses:** 0, 10, 30, 50, 70**Sample Size:** 67, 67, 67, 67, 67

The following 4 models (including input parameters) were evaluated in this MCP-Mod analysis and were found to have the following per-model power:

Emax (ED50): 10, 76.42%

Linear: 75.26%

Logistic (ED50, δ): 20, 1, 93.64%

Beta (a, b, Scale): 1.8, 1, 80, 75.85”